Movatterモバイル変換

[0]ホーム
URL:

WO2010062372A3 - Methods for modulating nf-kb using gibberellins - Google Patents

Methods for modulating nf-kb using gibberellinsDownload PDF

Info

Publication number
WO2010062372A3
WO2010062372A3PCT/US2009/005938US2009005938WWO2010062372A3WO 2010062372 A3WO2010062372 A3WO 2010062372A3US 2009005938 WUS2009005938 WUS 2009005938WWO 2010062372 A3WO2010062372 A3WO 2010062372A3
Authority
WO
WIPO (PCT)
Prior art keywords
gibberellins
diseases
modulating
methods
provides methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/005938
Other languages
French (fr)
Other versions
WO2010062372A2 (en
Inventor
Angela N. Koehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard UniversityfiledCriticalHarvard University
Publication of WO2010062372A2publicationCriticalpatent/WO2010062372A2/en
Publication of WO2010062372A3publicationCriticalpatent/WO2010062372A3/en
Anticipated expirationlegal-statusCritical
Ceasedlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

The present invention provides methods for modulating the NF-κB pathway in a cell using gibberellins such as gibberellic acid. The invention also provides methods for using gibberellins in treating proliferative diseases (e.g., cancer), neurodegenerative diseases, autoimmune diseases, inflammatory diseases, and infectious diseases.
PCT/US2009/0059382008-11-032009-11-03Methods for modulating nf-kb using gibberellinsCeasedWO2010062372A2 (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
US11072808P2008-11-032008-11-03
US61/110,7282008-11-03

Publications (2)

Publication NumberPublication Date
WO2010062372A2 WO2010062372A2 (en)2010-06-03
WO2010062372A3true WO2010062372A3 (en)2010-07-22

Family

ID=42226301

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2009/005938CeasedWO2010062372A2 (en)2008-11-032009-11-03Methods for modulating nf-kb using gibberellins

Country Status (1)

CountryLink
WO (1)WO2010062372A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10800730B2 (en)2012-03-232020-10-13The Board Of Trustees Of The University Of IllinoisComplex and structurally diverse compounds

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2012135651A1 (en)2011-03-312012-10-04The Procter & Gamble CompanySystems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
MX2014014898A (en)2012-06-062015-03-04Procter & GambleSystems and methods for identifying cosmetic agents for hair/scalp care compositions.
JOP20190260A1 (en)2017-05-022019-10-31Merck Sharp & DohmeStable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019022873A8 (en)2017-05-022023-04-11Merck Sharp & Dohme FORMULATION, AND, INJECTION VESSEL OR DEVICE.
CN108276370B (en)*2018-02-092022-02-15云南大学17-alkylthio gibberellin ester compound, preparation method and anti-tumor application thereof
CN110317179B (en)*2018-03-292023-01-24云南大学 Gibberellin-like compound, its preparation method, pharmaceutical composition and application and its intermediate
WO2019231805A1 (en)*2018-05-302019-12-05The Johns Hopkins UniversityNF-κB p50 DEFICIENT IMMATURE MYELOID CELLS AND THEIR USE IN TREATMENT OF CANCER
CA3116592A1 (en)*2018-10-312020-05-07Merck Sharp & Dohme Corp.Anti-human pd-1 antibody crystals and methods of use thereof
JP7503056B6 (en)2018-11-072024-07-16メルク・シャープ・アンド・ドーム・エルエルシー Co-formulation of anti-LAG3 and anti-PD-1 antibodies
CN113197893A (en)*2021-05-312021-08-03福建医科大学附属第一医院Application of gibberellin and derivatives thereof in preparation of medicines for preventing and/or treating central nervous system diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5580857A (en)*1989-12-121996-12-03Oden; PerUse of gibberellins for the treatment of prostatitis
US6121317A (en)*1995-01-062000-09-19Australian Biomedical Company Pty. Ltd.Gibberellins (including gibberellins A3 and A7) used in ulcer or wound healing
US6821737B2 (en)*2001-06-082004-11-23Panomics, Inc.Method for screening for drug candidates for modulating transcription factor activity
US20070128648A1 (en)*2002-05-242007-06-07Jun LiMethods for the Identification of IKKalpha Function and other Genes Useful for Treatment of Inflammatory Diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5580857A (en)*1989-12-121996-12-03Oden; PerUse of gibberellins for the treatment of prostatitis
US6121317A (en)*1995-01-062000-09-19Australian Biomedical Company Pty. Ltd.Gibberellins (including gibberellins A3 and A7) used in ulcer or wound healing
US6821737B2 (en)*2001-06-082004-11-23Panomics, Inc.Method for screening for drug candidates for modulating transcription factor activity
US20070128648A1 (en)*2002-05-242007-06-07Jun LiMethods for the Identification of IKKalpha Function and other Genes Useful for Treatment of Inflammatory Diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTRILLO, A. ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 19, 2001, pages 15854 - 15860*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10800730B2 (en)2012-03-232020-10-13The Board Of Trustees Of The University Of IllinoisComplex and structurally diverse compounds

Also Published As

Publication numberPublication date
WO2010062372A2 (en)2010-06-03

Similar Documents

PublicationPublication DateTitle
WO2010062372A3 (en)Methods for modulating nf-kb using gibberellins
WO2009155535A3 (en)Compositions, methods and kits for eliciting an immune response
WO2009016381A3 (en)Charcoals
WO2011142858A3 (en)Chlorotoxin variants, conjugates, and methods for their use
GB2447195B (en)Ion energy spread reduction for mass spectrometer
EP2325896A4 (en)Front electrode for solar cell which minimizes power loss, and solar cell including the same
WO2010011644A3 (en)Differentiated anucleated cells and method for preparing the same
EP2506505A4 (en)Load distribution system, load distribution method, and program
WO2009076676A3 (en)Compositions and methods for producing isoprene
EP2342834A4 (en)Beam forming method, apparatus and system
EP2303901B8 (en)Fosaprepitant dimeglumine intermediate, neutral fosaprepitant, and amorphous fosaprepitant dimeglumine and processes for their preparations
WO2011075636A3 (en)Wise binding agents and epitopes
WO2007067296A8 (en)Ion sources, systems and methods
EP2633546A4 (en)Fast-switching dual-polarity ion mobility spectrometry
WO2009158719A3 (en)Methods and compositions for treating disorders
WO2009114547A3 (en)Enhanced dendritic cells for cancer immunotherapy
EP2652524A4 (en)Dosimetry system, methods, and components
WO2008085990A3 (en)Systems for genome selection
EP2660849A4 (en)Mass spectrometry method, ion generation device, and mass spectrometry system
WO2011088076A3 (en)Structured rna motifs and compounds and methods for their use
WO2010062966A3 (en)Methods for inducing mixed chimerism
WO2009088939A3 (en)Compositions and methods for treating neurodegenerative diseases
WO2010111221A3 (en)Compositions and methods for preferential distribution of active agents to injury sites
WO2010002983A3 (en)Composition and methods for eliciting an immune response
WO2006052826A3 (en)Methods for preparing cells and viruses

Legal Events

DateCodeTitleDescription
121Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number:09829460

Country of ref document:EP

Kind code of ref document:A2

NENPNon-entry into the national phase

Ref country code:DE

122Ep: pct application non-entry in european phase

Ref document number:09829460

Country of ref document:EP

Kind code of ref document:A2
[8]ページ先頭
©2009-2025 Movatter.jp